COMPANY REGISTRATION NUMBER: 11119884
CHARITY REGISTRATION NUMBER: 1183996

Medics 4 Rare Diseases Ltd

Company Limited by Guarantee

Unaudited Financial Statements

31 December 2019

Medics 4 Rare Diseases Ltd

Company Limited by Guarantee

Financial Statements

Year ended 31 December 2019

Medics 4 Rare Diseases Ltd

Company Limited by Guarantee

Trustees' Annual Report (Incorporating the Director's Report)

Year ended 31 December 2019

The trustees, who are also the directors for the purposes of company law, present their report and the unaudited financial statements of the charity for the year ended 31 December 2019 .

Reference and administrative details

Registered charity name	Medics 4 Rare Diseases Ltd	
Charity registration number		1183996
Company registration number		11119884
Principal office and registered office	8 Silver Street Dursley Gloucestershire GL11 4ND	
The trustees	Dr D R Fine Mr C J France Dr O H Grant Mr D C Jeffries Mrs T Collin-Histed	 (Resigned 14 January 2020)
Company secretary	Dr L M R McKay	
Independent examiner	Howard Matthews BA FCA Queensgate House 23 North Park Road Harrogate North Yorkshire HG1 5PD	

Structure, governance and management

Trustees have been appointed to the M4RD based on their experience, skills and enthusiasm for the work of M4RD. M4RD relies heavily on the voluntary time that its Trustees generously provide. The minimum number of Directors is 2 and the there is not maximum number. Who can be considered for the position of Director is outlined in the company's Articles of Association.

Trustee induction is provided by the CEO with input from the Chair. This is carried out remotely. The new Trustee is provided with a New Trustee Induction Pack and access to the Charity's documents. M4RD makes use of readily available online training created by other organisations and provides a PDF copy of The Charity Commissions document "The Essential Trustee'.

The board meets roughly 6 times a year. The CEO, Lucy McKay, is a founding member of the company and has been in role as CEO since September 2018. Lucy has been employed by the Trustees to manage the day-to-day operations of the charity and to achieve the charity's aims and objectives. Lucy receives administrative support from Absolute Virtual Assistance on an ad-hoc basis.

Lucy reports to the Chair weekly and to the Treasurer monthly in order to ensure the smooth and financially prudent running of the charity. Both of these recurring meetings were initiated in 2019 and have been immensely valuable to the team as a whole.

The M4RD Board of Trustees greatly contribute to the success of the charity. Two Trustees are GPs and have been involved in M4RD (in its previous incarnations) since 2011. The Treasurer was an Accountant prior to retraining as a doctor. On the board we also have a Patient Organisation representative who helped M4RD establish itself as a charitable company. Our patient representative is also an author and public speaker. As well as doing his day job of creating online interactive educational software, he created the new website at no cost and oversees its proper functioning. The Chair is the founder of a successful online retail company and has been pivotal in getting M4RD's structure established.

The aims and objective of the 2018/2019 plan have driven the decision making during this period. The CEO is largely responsible for making decisions about activities that achieve the aims and objectives. 2019 required a lot of organisational change as the board worked with The Charity Commission to register the company as a charity. The Chair was predominantly responsible for this process but was supported by the CEO. Large financial decisions (outside of pre-authorised projects) are taken to the board by the CEO to be discussed. These usually constitute costs over £100.

Objectives and activities

The organisation is a charitable company limited by guarantee incorporated on 20th December 2017 and registered as a charity on 20th June 2019. The company was established under a Memorandum of Association which established the objects and powers of the company and is governed under its Articles of Association which were updated on 20th June 2019 in line with recommendations from the Charity Commission. In the event of the company being wound up, members are required to contribute an amount not exceeding £1.

Below are the charity's purposes as set out in the objects contained in the company's Memorandum of Association.

The company is established for the objects of the relief of sickness and preservation of health of those suffering from rare diseases, throughout the world, by:

(a) advancing the education of medics, associated professionals and the public in rare diseases, genetic and genomic medicine

(b) promoting research in all areas relating to rare diseases, genetic and genomic medicine and publishing the useful results

(c) promoting improved care and treatment of those suffering from rare diseases.

Aims and public benefit:

The charity aims to improve the lives of a certain portion of the public: those living with rare diseases and their communities. It does this through raising awareness of the relevance of rare diseases in medical practice. The charity provides education about rare diseases and opportunities to develop a clinician's understanding of this large population group in the UK in order to better serve it.

The trustees received guidance on public benefit from the Charity Commission during the registration process. The company's Articles of Association were updated on 20th June 2019 in line with recommendations from the Charity Commission. The organisation's objects are wholly charitable. Any personal benefit arising is legitimately incidental.

Review:

During 2019 M4RD worked with the Charity Commission to make sure its structure, objects and governing document were ready for the organisation to be registered as a charity. This required a review of our purposes to make sure they were wholly charitable and benefited the public. In the case of M4RD 'the public' refers to the estimated 3.5 million people in the UK who suffer from a rare disease - and their communities.

Following guidance from the Charity Commission the Board of Trustees adapted the company's original Memorandum & Articles to make sure the wording was suitable for the charity. The full Articles of Association can be viewed in the Filing History of M4RD on the Companies House website: beta.companieshouse.gov.uk/company/ 11119884 /filing-history.

Going forward the Board of Trustees will review M4RD's aims, objectives and activities on an annual basis. This will be done with reference to guidance contained in the Charity Commission’s general guidance on public benefit.

Activities:

A rare disease is defined by the European Union as a condition that affects fewer than 5 in 20,000 people. Over 7,000 rare diseases have been identified which means that understanding and teaching about rare diseases in medical education is unfeasible. However this is a challenge that we cannot afford to avoid because approximately 3.5 million people in the UK have a rare disease. So while each disease is individually rare, they are collectively common.

Of these diseases, 80% are known to be genetic in origin and 75% affect children. 30% of those living with a rare disease will sadly die before their fifth birthday. However, despite this impressive prevalence (akin to all adults in the UK who suffer with asthma), each individual condition affects so few people that they tend to be overlooked and misunderstood by health professionals, researchers, education and social care providers and the general public. This lack of awareness amongst medical professions is particularly devastating and can lead to extreme diagnostic delay. A person with a rare disease will wait on average 5.6 years for an accurate diagnosis. They will see numerous doctors, receive misdiagnoses and potentially even inappropriate treatment. This long and arduous journey to a diagnosis has been named "the diagnostic odyssey".

The challenges of having a rare disease do not stop after getting a diagnosis. People living with completely different diseases often report the same difficulties in terms of healthcare, social care, family life, education, work and mental health. There are many wonderful charities in the UK that support rare disease patients depending on their disease or specific need. Umbrella charities run successful public awareness campaigns. However M4RD specifically targets an audience that nobody else was concentrating on but could make the greatest impact on the diagnostic odyssey and the challenges that follow: medical students and doctors in training.

By creating a medical profession equipped to suspect, diagnose and manage rare diseases we can help people living with rare diseases have the best outcomes and reach their full potential. To do this M4RD is driving an attitude change towards rare diseases amongst medical students and doctors in training. Without appropriate training, the idea that rare diseases are irrelevant to clinical practice will continue to contribute to the diagnostic odyssey. We remedy this by presenting the statistics to our audience and asking people with rare diseases to share their stories. M4RD are also working on an approach to satisfactorily cover the subject of rare disease within undergraduate and post-graduate medical training. Finally, we're creating our own resources and promoting others' resources in order to support medical professionals when they need help on the subject of rare disease.

Wider network:

particular note are Findacure who M4RD partners with in order to run an essay competition that raises awareness of rare diseases and Cambridge Rare Disease Network and The British Paediatric Surveillance Unit. The annual symposium is organised in association with The Royal Society of Medicine, another UK registered charity.

M4RD also collaborates with other not-for-profit organisations such as Rare Revolution Magazine - an online digital magazine for the rare disease community and The International Gaucher Association with whom M4RD has an agreement to use their offices as a registered address.

M4RD receives pro bono support from the health communications agency, emotive.

Achievements and performance

M4RD continues to use a combination of inperson and online methods in order to reach medical professionals.

The M4RD annual symposium (known as The Unusual Suspects) is the only event that is organised solely by M4RD. Although it is held in association with The Medical Genetics Section of The Royal Society of Medicine, the agenda and the majority of the event organisation is the responsibility of the M4RD team. The 2019 symposium was a big success with more attendees than ever before.

Throughout 2019 the M4RD team helped medical students across the UK to hold their own rare disease events, for example students from St George's University produced an event on haemophilia. M4RD also promoted 10s of rare diseases events aimed at medical professionals. The events page started filling up nicely this year which shows a promising trend in medical education on rare diseases.

Lucy McKay spoke at a number of events about the purpose of M4RD and the need for the medical profession to DareToThinkRare. Her talk at the BPSU received positive feedback from The Deputy Chief Medical Officer who was in attendance. This has led to discussions with the Department of Health and Social Care about including specific guidelines on medical education in the next UK Rare Disease Strategy. It is important that M4RD not only focuses on the individual professionals but also on how to have training institutions adopt the M4RD approach to rare disease education. We are excited to see where these conversations lead in in 2020.

Website and social media:

As for producing and promoting learning resources, the new website has helped make this easier than ever. 2019 saw the launch of the new M4RD website, created by one of the Trustees, Dan Jeffries. m4rd.org is a hub for rare disease news, information, videos and resources aimed at medical professionals.People are increasingly expecting their learning materials and activities to be available online. This is a trend that M4RD is keen to accelerate because the diagnostic odyssey is a global issue and while M4RD is UK focused - our work is relevant around the world. The more medical professionals that we can reach the better! Additionally face-to-face events require a lot more time and money to produce than online events and resources. While online resources are more convenient and accessible to a larger audience. Therefore the team has concentrated on building up their online presence. We now have an established presence on Facebook, Twitter, Instagram and LinkedIn. More content is required to get the M4RD YouTube channel up and running properly.

In 2019 the M4RD team implemented a social media strategy that would help build its following and raise awareness of rare diseases. #MysteryDiseaseMonday is a fun feature that is run on Instagram stories every Monday. It started organically from Lucy's GP colleague texting her to ask "have you heard of Kikuchi-Fukimoto Disease?". The answer was "no" and Lucy decided to put it to the M4RD Instagram followers in a poll on Instagram Stories. 26 followers viewed this Story and of those who voted (number unknown) 82% had NOT heard of this condition. #MDM became a regular feature and 34 different conditions were polled in this way. This regularly engaged medical professionals and promoted the work of the patient groups who were involved. In a year the M4RD Instagram following grew by 325%. M4RD had a poster accepted to The 10th European Conference on Rare Diseases organised by EURORDIS outlining the benefits of running #MDM.

Ambassador programme:

After a successful pilot year M4RD decided to continue with the Ambassador Scheme for a second year.

Three clinical ambassadors continued in their positions. All three are Foundation Year 2 doctors and the board felt it important to have a senior clinician involved in the programme. Dr Gisela Wilcox, consultant in Metabolic Medicine at Salford Royal Hospital, generously volunteered her time. Since joining the M4RD family she has organised events for medical trainees at her hospital, raised the profile of M4RD during her work and been available to consult on our activities.

During 2019 the M4RD team received tragic news that Simran, our patient ambassador, had died during an operation for her heart condition. Simran was a founding director of Medics4RareDiseases in December 2017. She lived with a rare condition and despite suffering from severe symptoms she was always sunny and optimistic. She was keen to be involved in the mission of M4RD and was invaluable when advising on our activities. Our sincere condolences were sent to Simran's family and we are deeply grateful for the part she played in M4RD's establishment. We would like to thank all the M4RD Ambassadors for the free time that they dedicate to achieve M4RD's objects.

The Unusual Suspects 2019:

M4RD held its annual symposium (known as The Unusual Suspects) at The Royal Society for the 5th year. The 2019 symposium was a big success with more attendees than ever before. 67 delegates attended - the majority of which were medical students and doctors in training. During the event delegates heard from patients, advocates and doctors in order to give a rounded view of what living with a rare disease is like and how they can help their patients. Holding the symposium at this prestigious medical institution is a great honour for M4RD. There were a lot of changes within the RSM during 2018/2019 and so the event organisation was not as straightforward as usual however we were grateful to the Medical Genetics Section for supporting us throughout the process. They also reflected this in the cost of the venue and their services. The agenda included Dr Will Evans giving his perspective on rare disease in general practice. This is an important area for M4RD to tackle because this is the stage that many patients get delayed in their diagnosis. Will provided pragmatic tips for managing suspected and confirmed rare disease cases. Nicola Miller talked about her experience as a mother of a boy with a very rare dermatological condition. Rudy Benfredj explained how AI will aid doctors to diagnose rare diseases in the future. This talk was extremely well received and has since led to many fruitful opportunities for M4RD. Trustee, Dan Jeffries, told his story of being diagnosed with one of his rare diseases by students during an exam. For the first time we had the talks professionally recorded so that they can be watched again and again. They have been very useful for producing remote learning materials. Feedback from the event was fantastic and helped demonstrate the benefit that M4RD has on this large group of people. 100% of relevant delegates said that the event would impact their clinical practice and one delegate said ""This conference will empower me to consider rare diseases in the future when making a diagnosis and not shy away from a lack of understanding or knowledge of the specific disease."

The Student Voice Prize 2019;

This year M4RD worked in a 50:50 partnership with Findacure in order to produce The Student Voice Prize. This essay competition was started by Findacure and M4RD have been involved in it for several years. Our trustees have been responsible for marking the essays for a number of years and Lucy has played an increasing role in organising the competition. The medical school experiences of Lucy and the M4RD trustees have helped Findacure target medical students.

The aim of the competition is to provide an attractive opportunity (becoming a published author in a journal) to encourage medical students to research rare diseases, engage with the rare disease community and pass on what they learned to their peers. The questions are carefully designed to make this competition accessible across the globe.

This year there were more patient group pairings than last year, when this approach was started. One of the runners-up was involved in a patient group pairing, through which she spoke to a boy with fibrodysplasia ossificans (FOP) and his mother about mental health challenges associated with living with a rare disease; as well as caring for someone with a rare disease.

The winning essay also answered the question on the mental health impact of living with a rare disease. The winner spoke at the M4RD annual symposium in 2020.

Financial review

2019 represented the second year of a two year plan for M4RD. The aims of which were:

-Become a company limited by guarantee - achieved in December 2017
-Register with the Charity Commission - achieved in June 2019
-Rebrand to Medics4RareDiseases - achieved in June 2019
-Employ staff to ensure objects are met - achieved in September 2018
-Continue to hold annual symposium - achieved
-Increasingly use social media to raise awareness - achieved
-Create disease specific infograms for sharing on social media - achieved
- Establish an M4RD YouTube channel - achieved in 2019
-Develop website as a resource centre - achieved in 2019

This financial year is the second of a 2 year plan for which funding was secured in late 2017 and received in 2018 and 2019. In total £36,988 of funding for these two years was secured which supplemented £8,024.58 from the previous year. The majority of spending occurred in 2019 as 2018 was largely spent organising the company structure and preparing for registering as a charity. Therefore expenses outweigh income in 2019 because the majority of the funding for the two years was received in 2018 but spent in 2019.

£9,000 was received in sponsorship in 2019 (£5000 from SOBI and £3000 from Inventiva). At the end of the financial year a donation of £1000 was received from Ultragenyx in order to aid M4RD to continue its work. Also at the end of the year, sponsorship was received from two companies to the total amount of £20,000 which has been deferred because it is for activities taking place in 2020.

Total funds carried forward is £6, 904 and final cash position is £30,560.

Principal Funding Sources

The principal funding sources for this period were sponsorship and donations from commercial companies. For the 2018/2019 two year plan M4RD received funding from BioMarin, Inventiva, SOBI and Ultragenyx.

The risks that M4RD are exposed to are fairly low as its committed spend and running costs are still relatively low. Everyone works remotely and the charity doesn't own or rent property. There is only one member of staff and the majority of work is done 'in house' or pro bono. However next year the Charity would like to expand in order to meet its objects more effectively and at a faster rate. A financial software package was implemented in 2019 to support the charity's growth, the aim of which is to to help manage its increasing transaction complexity as it expands. The Treasurer, who formally worked as an accountant, has financial oversight.

M4RD is in the process of opening a bank account with CAF Bank in order to allow a deeper level of governance in terms of managing the finances.

The main financial risk is, as always, managing to secure future funding. So far M4RD has relied 100% on commercial donations and sponsorship. However now it is a registered charity the Board of Trustees would like to diversify revenue streams in order to ensure the charity can continue its work well into the future, until the diagnostic odyssey is no longer a problem faced by those with rare diseases.

Reserves policy and review:

The Trustees agreed that reserves need to be kept and put a Reserves Policy in place in 2019. Reserves are to be maintained at a level which ensures that the charity's core activity could continue during a 3 month period of unforeseen financial difficulty during which funding is to be secured. If funding is not secured then this is followed by a 3 month period in which the organisation could be dissolved with all outstanding debt settled. The Board of Trustees have set a minimum of £11,000 to be held in the charity's reserves. This is to ensure they are able to maintain running the charity and to meet its main objects for which it was created.

Plans for future periods

Future plans for the charity include:

Development of the 'Rare Disease 101 Project':

-Creating an online and interactive learning tool for remote learning use.

-Providing all the materials required for students and doctors to produce their own rare disease training day.

-Create a Rare Disease 101 video.

This project is the first step in campaigning for Rare Disease 101 education to be mandatory during medical school studies and in continued medical education.

Complete the Red Flags of Rare Disease Project and submit for publication. Continue building the resource centre for medics on the website's LEARN page. Organise the annual symposium at The Royal Society of Medicine in February 2020 Continue developing the 'M4RD Ambassadors' scheme & run it for a third year Produce the Student Voice Prize 2020 with Findacure

Organisational plans:

Complete transfer of bank account from Lloyds Bank to CAF Bank

Develop a more diverse fundraising strategy

Hire a Finance Officer

Convert to a Charitable Incorporated Company

Future funding:

In 2019 M4RD sent out a funding applications to companies involved in a wide range of rare diseases. The application explained the charity's plans for the future and estimated costs involved. In total the charity hopes to raise £70,000 to achieve the aims and objectives of 2020. In addition the M4RD team will be looking for a Finance Officer with experience in fundraising.

Events after the end of the reporting period

Particulars of events after the reporting date are detailed in note 16 to the financial statements.

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

The trustees' annual report was approved on 29 June 2020 and signed on behalf of the board of trustees by:

Mr C J France

Trustee

Independent Examiner's Report to the Trustees of Medics 4 Rare Diseases Ltd

Year ended 31 December 2019

I report to the trustees on my examination of the financial statements of Medics 4 Rare Diseases Ltd ('the charity') for the year ended 31 December 2019.

Responsibilities and basis of report

As the trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. **Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Howard Matthews BA FCA Independent Examiner
Queensgate House 23 North Park Road Harrogate North Yorkshire HG1 5PD
28 July 2020

Medics 4 Rare Diseases Ltd

Company Limited by Guarantee

Statement of Financial Activities

(including income and expenditure account)

Year ended 31 December 2019

		2019		2018
		Unrestricted funds	**Total funds**	Total funds
	Note	**£**	**£**	£
Income and endowments				
Donations and legacies	**5**	9,190	9,190	37,025
Total income		9,190	9,190	37,025
Expenditure				
Expenditure on charitable activities	**6,7**	29,070	29,070	10,241
Total expenditure		29,070	29,070	10,241
Net (expenditure)/income and net movement in funds		(19,880)	(19,880)	26,784
Reconciliation of funds				
Total funds brought forward		26,784	26,784	–
Total funds carried forward		6,904	6,904	26,784

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

Medics 4 Rare Diseases Ltd

Company Limited by Guarantee

Statement of Financial Position

31 December 2019

	Note	2019 £	2018 £
Current assets			
Cash at bank and in hand		30,560	30,971
Creditors: amounts falling due within one year	11	23,656	4,187
Net current assets		6,904	26,784
Total assets less current liabilities		6,904	26,784
Net assets		6,904	26,784
Funds of the charity			
Unrestricted funds		6,904	26,784
Total charity funds	14	6,904	26,784

For the year ending 31 December 2019 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These financial statements were approved by the board of trustees and authorised for issue on 29 June 2020 , and are signed on behalf of the board by:

Mr C J France

Trustee

1. General information

The charity is a public benefit entity and a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is 8 Silver Street, Dursley, Gloucestershire, GL11 4ND.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Companies Act 2006.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through income or expenditure.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Going concern

There are no material uncertainties about the charity's ability to continue.

Changes in accounting policies

The company obtained charitable status on 20 June 2019 and for the year ended 31 December 2019 has, in agreement with the Charity Commission, prepared it's financial statements in compliance with the Charities SORP. There has been no change in the business activity of the company since it's incorporation and the comparatives have been restated in light of using the Charities SORP.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees to further any of the charity's purposes. Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment. Restricted funds are subjected to restrictions on their expenditure declared by the donor or through the terms of an appeal, and fall into one of two sub-classes: restricted income funds or endowment funds.

Incoming resources

All incoming resources are included in the statement of financial activities when entitlement has passed to the charity; it is probable that the economic benefits associated with the transaction will flow to the charity and the amount can be reliably measured. The following specific policies are applied to particular categories of income: - income from donations or grants is recognised when there is evidence of entitlement to the gift, receipt is probable and its amount can be measured reliably. - legacy income is recognised when receipt is probable and entitlement is established. - income from donated goods is measured at the fair value of the goods unless this is impractical to measure reliably, in which case the value is derived from the cost to the donor or the estimated resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliably measured. No amounts are included for the contribution of general volunteers. - income from contracts for the supply of services is recognised with the delivery of the contracted service. This is classified as unrestricted funds unless there is a contractual requirement for it to be spent on a particular purpose and returned if unspent, in which case it may be regarded as restricted.

Resources expended

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial activities to which it relates: - expenditure on raising funds includes the costs of all fundraising activities, events, non-charitable trading activities, and the sale of donated goods. - expenditure on charitable activities includes all costs incurred by a charity in undertaking activities that further its charitable aims for the benefit of its beneficiaries, including those support costs and costs relating to the governance of the charity apportioned to charitable activities. - other expenditure includes all expenditure that is neither related to raising funds for the charity nor part of its expenditure on charitable activities.

All costs are allocated to expenditure categories reflecting the use of the resource. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs are apportioned between the activities they contribute to on a reasonable, justifiable and consistent basis.

Financial instruments

A financial asset or a financial liability is recognised only when the charity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs. Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted. Debt instruments are subsequently measured at amortised cost. Where investments in shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in income and expenditure. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in the statement of financial activities, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised under the appropriate heading in the statement of financial activities in which the initial gain was recognised. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as an expense in the period in which it arises.

4. Limited by guarantee

Medics 4 Rare Disease Ltd is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

5. Donations and legacies

	Unrestricted Funds £	**Total Funds 2019 £**	Unrestricted Funds £	Total Funds 2018 £
Donations				
Donations	1,190	1,190	1,000	1,000
Sponsorship				
Sponsorship	8,000	8,000	36,025	36,025
	9,190	9,190	37,025	37,025

6. Expenditure on charitable activities by fund type

	Unrestricted Funds £	**Total Funds 2019 £**	Unrestricted Funds £	Total Funds 2018 £
Medical education	26,429	26,429	9,376	9,376
Support costs	2,641	2,641	865	865
	29,070	29,070	10,241	10,241

7. Expenditure on charitable activities by activity type

	Activities undertaken directly	Support costs	**Total funds 2019**	Total fund 2018
	£	£	**£**	£
Medical education	26,429	–	26,429	9,376
Governance costs	–	2,641	2,641	865
	26,429	2,641	29,070	10,241

8. Independent examination fees

	2019	2018
	£	£
Fees payable to the independent examiner for:		
Independent examination of the financial statements	900	–
Other assurance services	1,741	865
	2,641	865

9. Staff costs

The total staff costs and employee benefits for the reporting period are analysed as follows:

	2019	2018
	£	£
Wages and salaries	14,570	3,950
Social security costs	670	–
Employer contributions to pension plans	346	–
	15,586	3,950

The average head count of employees during the year was 1 (2018: 1). The average number of full-time equivalent employees during the year is analysed as follows:

	2019	2018
	No.	No.
Charitable activities	1	1

No employee received employee benefits of more than £60,000 during the year (2018: Nil).

10. Trustee remuneration and expenses

No remuneration or other benefits from employment with the charity or a related entity were received by the trustees.

11. Creditors: amounts falling due within one year

	2019	2018
	£	£
Accruals and deferred income	23,279	4,187
Social security and other taxes	377	–
	23,656	4,187

12. Deferred income

	2019	2018
	£	£
Amount deferred in year	20,000	–

13. Pensions and other post retirement benefits

Defined contribution plans

The amount recognised in income or expenditure as an expense in relation to defined contribution plans was £ 346 (2018: £Nil).

14. Analysis of charitable funds

Unrestricted funds

	At 1 January 2019	Income	Expenditure	**At 31 December 2019**
	£	£	£	£
General funds	26,784	9,190	(29,070)	6,904

	At 1 January 2018	Income	Expenditure	At 31 December 2018
	£	£	£	£
General funds	–	37,025	(10,241)	26,784

15. Analysis of net assets between funds

	Unrestricted Funds	**Total Funds 2019**
	£	**£**
Current assets	30,560	30,560
Creditors less than 1 year	(23,656)	(23,656)
Net assets	6,904	6,904

	Unrestricted Funds	Total Funds 2018
	£	£
Current assets	30,971	30,971
Creditors less than 1 year	(4,187)	(4,187)
Net assets	26,784	26,784

16. Post balance sheet events

A special resolution was agreed and passed on 14 January 2020 to convert the charitable company to a charitable incorporated organisation (CIO) without changes to the organisation's name, details or Memorandum and Articles of Association.